DESSOLVE III also includes an OCT sub-study evaluation of 60 patients (30 MiStent SES, 30 Xience) at six and 24 months post-treatment to evaluate and compare for superiority of MiStent SES against Xience in the progression of in-stent percent volume obstruction and frequency of neoatheroma formation over time.
Patrick Serruys, M.D., Ph.D., International Center for Circulatory Health, NHLI, Imperial College, London, UK
William Wijns, M.D., Ph.D., Cardiovascular Center, Aalst, Belgium
Robbert de Winter, M.D., Ph.D., Academisch Medisch Centrum, Amsterdam, The Netherlands
More information on the DESSOLVE III trial can be found here.